Brief: Dong-A St Co Completes Global 3Rd Phase Clinical Trial For Its Stelara Biosimilar
16/11/2022 23:39
Dong-A ST Co Ltd 170900.KS :
* DONG-A ST CO: COMPLETES GLOBAL 3RD PHASE CLINICAL TRIAL
FOR ITS
STELARA BIOSIMILAR
Source text for Eikon: ID:
Further company coverage: 170900.KS
Recent news on Dong-A ST
See all newsBrief: Dong-A St Q1 Operating Profit 10.8 Billion Won, Up 53.7% From Year Earlier
Brief: Dong-A St To Cancel 5 Billion Won Worth Of Own Shares
Brief: Dong-A St Q4 Operating Loss 554 Million Won
Brief: Dong-A St Q2 Operating Profit 4 Billion Won, Down 43.4% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 7 Billion Won, Up 854% From Year Earlier